The human gut is a bustling metropolis of trillions of microbes, a hidden world that Professor Sam Forster is determined to bring to light. While many view bacteria as mere enemies, Forster's research reveals their profound impact on our health. These microscopic organisms are not just digestive aides; they wield influence over our immunity, disease susceptibility, and even mood. Forster's work is a testament to the potential of these tiny creatures, as he harnesses them to create groundbreaking treatments for conditions like inflammatory bowel disease and stubborn infections.
Forster's journey began at the Wellcome Sanger Institute in Cambridge, where he collaborated with Professor Trevor Lawley. The challenge was twofold: identifying gut microbes through DNA sequencing and growing them in the lab. This crucial step is essential for understanding their functions and potential as therapies. As Forster explains, "If you want to turn microbes into treatments, sequencing isn't enough. You need to grow them, study them, and produce enough to use safely in people."
Microbiome-led approaches, such as fecal microbiota transplantation (FMT), have already demonstrated remarkable success in treating chronic Clostridioides difficile infections and inflammatory bowel disease. FMT involves taking a complex community of microbes from a healthy individual and using it to reset another person's system, leading to real, measurable improvements. This is a powerful reminder of the potential within these microbial communities.
Forster envisions a future where modifying the microbiome becomes a standard treatment for immune-related diseases, from inflammatory bowel disease to autoimmune conditions like arthritis. He notes, "Any disease linked to the immune system could be improved by adjusting the gut microbiome."
Public awareness of gut health is on the rise, fueled by technological advancements, scientific discoveries, and proven treatments like FMT. Forster emphasizes, "Once you can grow these bacteria and test them, you can design therapies tailored to specific conditions."
Forster's current focus is on developing a designed bacterial mix for inflammatory bowel disease (IBD) in clinical trials, in collaboration with BiomeBank, an Adelaide-based startup. This progress is made possible by a fellowship grant from CSL, which supports long-term collaborative research. Forster acknowledges, "Science alone isn't enough. We need a pathway to take discoveries from the lab and turn them into therapies that reach patients safely and effectively."
The CSL fellowship grant enables Forster's team to build the foundations for these therapies, focusing on experiments that pave the way for real-life outcomes. Clinical trials are already underway, and Forster is optimistic that within the next five years, refined microbiome-based treatments could become standard medical practice. He concludes, "It's very plausible we'll have treatments for a number of conditions. The trials are happening now, and progress is moving quickly... It's realistic to expect these therapies could become part of conventional medicine."
Forster's work extends beyond the laboratory, as he collaborates with BiomeBank to deliver microbiome treatments to patients across Australia. His goal is to make microbiome medicine precise, personal, and practical, ensuring that these therapies reach everyone who needs them. By matching the right microbes to the right patients, Forster believes they can change the course of disease, offering hope for a healthier future.
